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ABSTRACT 
Background and purpose Antagonists of the N-type voltage gated calcium channel (VGCC), 
Cav2.2, have a potentially important role in the treatment of chronic neuropathic pain.  ω-
Conotoxins, such MVIIA and CVID are effective in neuropathic pain models. CVID is reported 
to have a greater therapeutic index than MVIIA in neuropathic pain models, and it has been 
suggested that this is due to faster reversibility of binding, but it is not known whether this can be 
improved further.  
Experimental approach. We examined the potency of CVID, MVIIA and two intermediate 
hybrids ([K10R]CVID and [R10K]MVIIA) to reverse signs of neuropathic pain in a rat nerve 
ligation model in parallel with production of side effects.  We also examined the potency and 
reversibility to inhibit primary afferent synaptic neurotransmission in rat spinal cord slices. 
Key results. All ω-conotoxins produced dose-dependent reduction in mechanical allodynia. They 
also produced side-effects on the rotarod test and in a visual side-effect score. CVID displayed a 
marginally better therapeutic index than MVIIA. The hybrids had a lesser effect in the rotarod 
test than either of their parent peptides. Finally, the conotoxins all presynaptically inhibited 
excitatory synaptic neurotransmission into the dorsal horn, and displayed recovery which was 
largely dependent upon the magnitude of inhibition and not the conotoxin type.  
Conclusions and Implications. These findings indicate that CVID provides only a marginal 
improvement over MVIIA in a pre-clinical model of neuropathic pain, which appears to be 
unrelated to reversibility from binding. Hybrids of these conotoxins might provide viable 
alternative treatments. 
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Introduction 
Neuropathic pain caused by damage to peripheral nerves, the spinal cord, or brain by physical 
trauma and disease is a debilitating pain state. This is characterised by a persistent abnormal pain 
syndrome that includes allodynia, spontaneous pain, dysesthesia, plus a range of psychosocial 
problems (Jensen et al., 2011). Chronic neuropathic pain is problematic because currently 
recommended pharmacological treatments have limited, or variable efficacy and are often 
associated with intolerable side-effects (Dworkin et al., 2010).  
 
Voltage gated calcium channel (VGCC) antagonists represent a potentially important class of 
analgesic agents for neuropathic pain (for review see McGivern, 2006; Adams et al., 2012). Of 
particular interest are the N-type VGCCs, Cav2.2 (Alexander et al., 2011), localised on 
nociceptive primary afferent neurons and their terminals within the superficial dorsal horn 
(Westenbroek et al., 1992; Snutch, 2005). A number of structurally related ω-conotoxins, 
including MVIIA, GVIA and CVID, have been extracted from the genus Conus (cone snails) 
which selectively inhibit Cav2.2 VGCCs (Adams et al., 2012; Lewis et al., 2012). Synthetic 
derivatives of MVIIA (Prialt, SNX-111, ziconotide) and CVID (AM336) have shown clinical 
potential, but must be delivered spinally to remain safe (McGivern, 2006). Preclinical studies 
have shown that intrathecally delivered MVIIA and CVID reduce the allodynia associated with 
rodent models of neuropathic pain (Chaplan et al., 1994; Bowersox et al., 1996; Scott et al., 
2002; Blake et al., 2005; Souza et al., 2008; Hama & Sagen, 2009; Berecki et al., 2010; Ogawa et 
al., 2011; Morimoto et al., 2012). While the spinal analgesic actions of both MVIIA and CVID 
are associated with a number of side-effects, CVID displays a much greater therapeutic index 
than MVIIA (Wright et al., 2000; Scott et al., 2002; Smith et al., 2002).  
 
The improved therapeutic index of CVID versus MVIIA could be due to a number of factors, 
including greater selectivity of CVID for Cav2.2 versus Cav2.1 (P/Q-type) calcium channels, and 
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differences in their biophysical properties, or pharmacokinetic profiles (Lewis et al., 2000; 
Mould et al., 2004; McGivern, 2006). One difference between these conotoxins is that the 
inhibition of VGCC currents in isolated neurons produced by CVID is more reversible after 
washout than for MVIIA, and this is due largely to one residue of the peptide sequence (Mould et 
al., 2004). Mutation of position 10 of the peptide CVID ([K10R]CVID) impairs the reversibility 
of VGCC inhibition, while mutation in MVIIA ([R10K]MVIIA) increases the reversibility 
(Adams et al., 2003; Mould et al., 2004).  
 
In the present study we compared the analgesic and side-effects produced by intrathecal 
administration of the ω-conotoxins CVID, MVIIA and the hybrids, [K10R]CVID and 
[R10K]MVIIA, in a rat model of neuropathic pain to determine whether or not substitution of this 
residue altered the therapeutic index of either CVID or MVIIA. In vitro slice studies have shown 
that Cav2.2 VGCC blockers MVIIA and CVID reduce primary afferent evoked excitatory 
postsynaptic currents (EPSCs) in superficial dorsal horn neurons via a presynaptic mechanism 
(Rycroft et al., 2007; Motin & Adams, 2008). We also therefore compared their effects on 
primary afferent evoked synaptic transmission into the superficial dorsal horn to determine 
whether their pain relieving actions were reflected in their spinal cellular actions.  
 
 5 
Methods 
Experiments were carried out on 2 – 3 week old (electrophysiology) and 8 – 10 week old 
(behaviour) Sprague-Dawley rats, following the guidelines of the ‘NH&MRC Code of Practice 
for the Care and Use of Animals in Research in Australia’ and with the approval of the Royal 
North Shore Hospital Animal Care and Ethics Committee. Animals were housed under a 12:12 
hour light/dark cycle, with environmental enrichment and free access to water and standard rat 
chow. 8 – 10 week old animals were housed in groups of three; 2 – 3 week old animals were 
housed with their littermates and mother. 
 
Reagents 
The ω-conotoxins CVID, MVIIA, [K10R]-CVID and [R10K]-MVIIA were synthesised as 
described previously (Adams et al., 2003). 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), dl-(-)-
2-amino-5-phosphonopentanoic acid (AP5) and n-ethyllidocaine bromide (QX314) were from 
Ascent Scientific (Bristol, U.K.); picrotoxin, strychnine hydrochloride and all other reagents were 
from Sigma (Sydney, Australia). 
 
Behavioural experiments 
Behavioural experiments were carried out on adult male rats as previously (Ekberg et al., 2006; 
Vuong et al., 2008). All animals were allowed to acclimatize to their holding cages for 2–3 days 
before any procedures were carried out. All surgical procedures were carried out under isoflurane 
(1–3 % in O2) anaesthesia. Rats underwent partial ligation of the sciatic nerve (PNL) (Seltzer et 
al., 1990). The left sciatic nerve was exposed at mid-thigh level approximately 3 mm proximal to 
the trifurcation of the sciatic nerve at the popliteal fossa. A 4-0 silk suture was inserted into the 
nerve to tightly ligate the dorsal 1/3–1/2 of the nerve trunk. The muscle (4-0) and skin (3-0) were 
closed with silk sutures. 9 days after PNL surgery, chronic polyethylene lumbar intrathecal 
catheters were inserted between vertebrae L5–6, advanced 3 cm rostrally and exteriorised via the 
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occipital region. 
 
To assess mechanical allodynia, the mechanical paw withdrawal threshold (PWT) was measured 
with a series of von Frey hairs (range 0.4–15 g) and calculated using the up-down paradigm 
(Chaplan et al., 1994). A plantar tester (Ugo Basile, Italy) was used to measure thermal pain. Rats 
were placed in Perspex enclosures (15 × 15 × 18 cm). Focal infrared heat was applied through the 
glass bottom of the enclosure to the left hind paw and the time for the rat to respond by moving 
its paw away from the noxious heat source was recorded (thermal paw withdrawal latency, 
PWL). Rats were given 10–15 min to acclimate to each of these devices before measurements 
were taken. To assess side-effects, motor performance was measured as the duration for which 
the animal could maintain balance on the rotating drum of a rotarod device (Ugo Basile, Italy), 
with a maximal cut-off time of 300 s. A qualitative scoring of side-effects was also used (Scott et 
al., 2002). Over the first two hours after drug injection, animals were scored as follows: 0 if no 
side-effects, 1 if mild side-effects (occasional spontaneous tail twitching, lower back hunching, or 
piloerection), 2 if moderate side-effects (frequent tail flicks or occasional writhing of the tail and 
spontaneous hind-limb twitching accompanied by ataxia, and frequent urination), 3 if severe side-
effects (marked tail writhing occurred along with frequent hind-limb twitching or hind-limb 
splaying and an inability to walk normally).  
 
All procedures were carried out in the light cycle. Animals were acclimatised to the testing 
devices before and 7 days after PNL surgery, then before intrathecal catheter placement. 
Solutions of all agents were made up just prior to administration. All agents were made up in a 
vehicle solution of normal saline, and injected intrathecally in a total volume of 20 µl, followed 
by a 15 µl flush of normal saline. Each animal underwent one drug injection experiment. On this 
day testing was carried out twice out over a 30 min period before, then at set time points over a 4 
- 6 hour period following intrathecal drug injection. The experimenter was blind to the drug being 
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tested. Afterwards, catheter placement was confirmed by the occurrence of rapid, bilateral hind 
limb paralysis following intrathecal injection of lignocaine (2 %). Conotoxins were injected at 
doses between 0.01–0.3 nmol, which corresponded approximately to 0.1–3 µg.kg-1. The highest 
dose of conotoxin tested was that at which a maximal side-effect score was observed in two, or 
more animals. 
 
Electrophysiological experiments 
Electrophysiological experiments were carried out as described previously (Jeong et al., 2010). 
Animals were deeply anaesthetized with isoflurane and decapitated. The spinal cord was 
exposed, the dura was incised and the spinal column quickly removed and placed in ice cold 
artificial cerebrospinal fluid (ACSF) of composition: (mM): NaCl, 126; KCl, 2.5; NaH2PO4, 1.4; 
MgCl2, 1.2; CaCl2, 2.4; glucose, 11; NaHCO3, 25. Transverse (300 µm) slices of the lumbar 
spinal cord (L4–6) were obtained using a vibratome (VT1000S: Leica, Nussloch, Germany) and 
maintained at 32–34 C in a submerged chamber containing ACSF equilibrated with 95% O2 and 
5% CO2. Individual slices were transferred to a slice chamber (volume 0.5 mL) and superfused 
continuously (2.2–2.5 ml.min-1) with ACSF at 32–34 C using an inline temperature controller.  
 
Superficial dorsal horn neurons located throughout lamina II were visualized using infra-red 
Dodt-tube, or Nomarski optics on an upright microscope (Olympus BX50, Olympus, Sydney, 
Australia) and whole-cell voltage clamp recordings (holding potential -65 mV, liquid junction 
potential corrected) were made using an Axopatch 200B (Molecular Devices, Sunnyvale, CA, 
USA). The internal solution contained (mM): CsCl 140, HEPES 10, EGTA 0.2, MgCl2 1, QX-
314 3, MgATP 2 and NaGTP 0.3 (pH 7.3 and osmolality 280– 285 mosmol.l-1). Series resistance 
(< 25 MΩ) was compensated by 80 % and continuously monitored during experiments. 
Electrically evoked EPSCs were elicited in neurons via a glass unipolar stimulating electrode 
placed on the dorsal root (once every 12 s, intensity 2 - 25 V, 0.1–0.3 ms) in the presence of the 
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GABAA channel blocker picrotoxin (100 µM), the glycine receptor antagonist strychnine (3 
µM) and the NMDA receptor antagonist AP5 (25 µM). The evoked EPSCs were classified as 
monosynaptic if the initial EPSC displayed little variability in its onset (Berry & Pentreath, 
1976). Stock solutions of all conotoxins were diluted (1:1,000–10,000) to working concentrations 
in ACSF immediately before use and applied by superfusion to the slice chamber. 
 
Analysis 
For behavioural experiments, comparisons of drug effects over time were made using two-way 
ANOVAs, with time and drug treatment as a within- and between-subjects factors (Prism, 
GraphPad Software, La Jolla, USA). When two-way ANOVAs were significant post-hoc 
comparisons between drug treatment groups and vehicle at individual time points were made 
using the Bonferroni adjustment for multiple comparisons. Dose response profiles in behavioural 
experiments were calculated as an average over the 1 and 2 hour time points post-drug injection 
(time at which maximal effects were observed) and transformed into their maximum possible 
effect (% MPE): mechanical PWT = (drug – pre-drug) / (15 – pre-drug); rotarod = (pre-drug –
drug) / (pre-drug); side-effect = (drug) / 3. The %MPE values were compared using one-way 
ANOVAs (or Kruskal-Wallis non-parametric test for side-effect scores) and when significant, 
post-hoc comparisons between drug treatment groups and vehicle were made using Dunnett’s (or 
Dunn’s) adjustment for multiple comparisons. The ED50s were calculated for % MPE data using 
a sigmoidal fit with a variable slope (Prism). 
 
For electrophysiological experiments, recordings were filtered (2 kHz low-pass filter) and 
sampled (10 kHz) for on-line and off-line analysis using AxographX (Axograph Scientific, 
Sydney Australia). Evoked EPSC amplitude was measured as the difference between the peak of 
the EPSC and a 2 ms baseline period preceding the stimulus artefact, and values were calculated 
as the mean over a 2 min period. The drug effect was calculated as follows: drug inhibition (%) = 
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(pre-drug – drug) / (pre-drug), recovery following 20 min drug washout (%) = (post-drug – 
drug) / (pre-drug – drug). Statistical assessment of individual drug effects were made using paired 
t-tests. Differences were considered significant when p < 0.05 and all numerical data are 
expressed as mean ± s.e.mean. 
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Results 
Effect of intrathecal conotoxins in a neuropathic pain model 
In animals which underwent partial sciatic nerve ligation and chronic implantation with lumbar 
intrathecal catheters, the mechanical PWT was 14.9 ± 0.1 g prior to PNL surgery, 0.7 ± 0.1 g at 9 
days post-PNL surgery (prior to intrathecal catheterisation) and 0.6 ± 0.6 g at 14 days post-PNL 
surgery (4 days after intrathecal catheterisation, n = 65). The thermal PWL was 7.7 ± 0.5, 6.8 ± 
0.8 and 6.2 ± 0.4 s, while the rotarod latency was 143 ± 9, 103 ± 11 and 86 ± 8 s, at the same time 
points.  
 
The intrathecal actions of the conotoxins of a 0.1 nmol dose (~ 1 µg.kg-1) of CVID and MVIIA, 
plus the hybrids [K10R]CVID and [R10K]MVIIA were first examined at 14 days post-PNL 
surgery (4 days post-intrathecal catherisation). The effect of CVID, [K10R]CVID, 
[R10K]MVIIA, MVIIA and vehicle on mechanical PWT differed significantly over time (p < 
0.0001, F(20, 205) = 8.1). CVID (n = 11) produced a reversible increase in mechanical PWT 
which was significantly greater than vehicle (n = 17) at 1–4 hours post-injection (Figure 1A, p < 
0.01–0.001). MVIIA (n = 6) and [R10K]MVIIA (n = 6) produced the greatest increase in 
mechanical PWT and this was significantly greater than vehicle at 1–6 hours post-injection 
(Figure 1A, p < 0.001–0.0001, MVIIA and [R10K]MVIIA). [K10R]CVID (n = 6) produced a 
lesser increase in mechanical PWT which was only significantly greater than vehicle at 2 hours 
post-injection (Figure 1A, p < 0.01). It might also be noted that while the increase in mechanical 
PWT produced by CVID and [K10R]CVID returned to pre-injection levels by 4 – 6 hours, the 
increase in mechanical PWT produced by MVIIA and [R10K]MVIIA remained above pre-
injections at 6 hours (Fig 1A). 
 
The effect of CVID, [K10R]CVID, [R10K]MVIIA, MVIIA (0.1 nmol) and vehicle on thermal 
PWL differed significantly over time (p < 0.0001, F(20, 175) = 3.1). MVIIA (n = 6) produced an 
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increase in thermal PWL which was significantly greater than vehicle (n = 11) only at 1 hour 
post-injection (Figure 1B, p < 0.0001, MVIIA and vehicle). CVID (n = 11), [K10R]CVID (n = 6) 
and [R10K]MVIIA (n = 6) did not produce an increase in thermal PWL relative to vehicle 
(Figure 1B, p > 0.05, CVID, [K10R]CVID and [R10K]MVIIA).  
 
The effect of CVID, [K10R]CVID, [R10K]MVIIA, MVIIA (0.1 nmol) and vehicle on rotarod 
latency differed significantly over time (p < 0.0001, F(16, 124) = 3.8). MVIIA (n =6) produced a 
sustained decrease in rotarod latency which was significantly greater than vehicle (n = 12) at 1–6 
hours post-injection (Figure 1C, p < 0.05–0.001, MVIIA and vehicle). CVID (n = 6) produced a 
reversible decrease in rotarod latency which was significantly greater than vehicle (n = 6) at 1 - 2 
hours post-injection (Figure 1C, p < 0.01–0.0001). [K10R]CVID (n = 6) and [R10K]MVIIA (n = 
6) did not produce a significant change in rotarod latency relative to vehicle (Figure 1C, p > 
0.05).  
 
Conotoxins produce dose dependent analgesia and side-effects 
We next examined the dose response profiles of the conotoxins. The net change in mechanical 
PWT and thermal PWL produced by vehicle and the various doses of CVID, [K10R]CVID, 
[R10K]MVIIA and MVIIA differed (p < 0.0001, p = 0.04, n = 5 - 17). CVID produced a net 
increase in mechanical PWT which was significantly greater than vehicle only at the 0.1–0.3 
nmol doses (Figure 2A, p < 0.001). [K10R]CVID, [R10K]MVIIA and MVIIA produced a net 
increase in mechanical PWT which was significantly greater than vehicle at the highest doses 
tested (Figure 2A, p < 0.001 at 0.3, 0.1 and 0.1 nmol). By contrast, CVID, [K10R]CVID, 
[R10K]MVIIA did not produce a change in thermal PWL significantly different to vehicle (p > 
0.05), while MVIIA produced a net increase in thermal PWL significantly greater than vehicle at 
the 0.1 nmol dose (p < 0.01, data not shown). 
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The decrease in rotarod latency and the side-effect score produced by vehicle and the various 
doses of CVID, [K10R]CVID, [R10K]MVIIA and MVIIA differed significantly (p < 0.0001). 
CVID (0.1, 0.3 nmol) and MVIIA (0.1 nmol) produced a decrease in rotarod latency which was 
significantly greater than vehicle only at the higher doses (Figure 2B, p < 0.001). [K10R]CVID 
did not produce a significant change in rotarod latency compared to vehicle (Figure 2B, p > 0.05). 
[R10K]MVIIA produced a decrease in rotarod latency which was significantly greater than 
vehicle only at the 0.1 nmol dose (Figure 2B, p < 0.05). The side-effect score was significantly 
different to vehicle at the higher doses of CVID (0.1, 0.3 nmol), [K10R]CVID (0.3 nmol), 
[R10K]MVIIA (0.1 nmol) and MVIIA (0.03, 0.1 nmol) (Figure 2C, p < 0.05–0.001).  
 
The therapeutic index (TI) for CVID and MVIIA, calculated as the ratio of the ED50s for the 
rotarod and side-effect score relative to mechanical PWT, was marginally greater for CVID (1.8, 
2.4) than that for MVIIA (1.0, 0.7) (Table 1). Dose response curves could not be fit to all of the 
data for the hybrids, so we compared the magnitude of the effect of all conotoxins on mechanical 
PWT to that for the rotarod and side-effect score, for doses at which there was a significant 
increase in mechanical PWT (Figure 2D, E). The hybrids [K10R]CVID and [R10K]MVIIA, but 
not their parent conotoxins CVID and MVIIA had a lesser effect on rotarod performance 
compared to mechanical PWT (Figure 2D). All of the conotoxins had a similar effect on the side-
effect score compared to mechanical PWT (Figure 2E). 
 
Effect of CVID, MVIIA and hybrids on synaptic transmission into superficial dorsal horn 
We next examined the effect of CVID on monosynaptic afferent-evoked synaptic transmission. 
Electrical stimulation of the dorsal root in the presence of strychnine (3 μM) and picrotoxin (100 
μM) produced evoked excitatory postsynaptic currents (EPSCs) in neurons throughout lamina II 
of the lumbar dorsal horn which were abolished by the non-NMDA antagonist CNQX (5 µM, 
n=4). Superfusion of CVID produced a decrease in the amplitude of evoked EPSCs (Figure 3A, 
 13 
B). The inhibition of the amplitude of evoked EPSCs produced by CVID was concentration 
dependent, with an EC50 of 69 nM (95 % confidence interval = 53–90 nM) and a hill slope of 2.1 
± 0.5 (Figure 3A, B, D, n= 3 - 15). When paired EPSCs were evoked at an inter-stimulus interval 
of 70 ms in these neurons, paired pulse depression was observed (paired-pulse ratio = 0.39 ± 
0.10, range = 0.06 - 0.70, n = 9) (Figure 3C). In the presence of CVID (100–1000 nM) the paired 
pulse ratio was increased to 150 ± 16 % of the pre-CVID level (p = 0.01). The increase in paired 
pulse ratio produced by CVID had an EC50 of 102 nM (95 % confidence interval = 15–354 nM). 
 
We also examined the actions of [K10R]CVID, [R10K]MVIIA and MVIIA at a concentration of 
100 nM which was just above the EC50 concentration for CVID. Superfusion of 100 nM 
[K10R]CVID (n = 5), [R10K]MVIIA (n = 5) and MVIIA (n = 6) all produced a decrease in the 
amplitude of evoked EPSCs (Figure 4A - D, p = 0.0009, 0.02, 0.0009). The inhibition produced 
by [R10K]MVIIA was less than that produced by CVID, [K10R]CVID and MVIIA ( p < 0.01).  
 
It has previously been reported that conotoxins vary in their rate of recovery from binding. We 
examined recovery of EPSC inhibition in neurons in which only one conotoxin was applied for 
10 min at a 100 nM concentration. Following 20 min washout, the amplitude of evoked EPSCs 
recovered to the pre-drug level for [R10K]MVIIA (p = 0.6, n = 5), but not for CVID (p = 0.0002, 
n = 8), [K10R]CVID (0.006, n = 5) and MVIIA (0.001, n = 6) (Figure 5C). In these experiments, 
however, the recovery of evoked EPSCs was highly variable following washout of each of the 
conotoxins (Figure 5A - C). The recovery from inhibition was inversely related to the inhibition 
during drug application for CVID, [K10R]CVID, [R10K]MVIIA and MVIIA (Fig 5D). The slope 
of recovery versus inhibition plots for the different conotoxins were not significantly different (p 
= 0.5, F(4, 38) = 0.87, pooled slope = -2.5 ± 0.3).  
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Discussion 
In the present study it has been demonstrated that the conotoxins CVID, MVIIA and two 
intermediate hybrids, [K10R]CVID and [R10K]MVIIA, reduce the allodynia-like pain behaviour 
associated with a nerve injury model of neuropathic pain. CVID displayed a marginally better 
therapeutic index than MVIIA. In addition, the hybrids had a relatively lesser effect on motor 
performance, but displayed other side-effects which were similar to CVID and MVIIA. The 
analgesic actions of the different conotoxins were likely to be mediated by a similar presynaptic 
inhibition of excitatory transmission into the superficial dorsal horn.  
 
In the present study, it was observed that intrathecal delivery of the conotoxins CVID and MVIIA 
produced an increase in mechanical PWT in animals which had undergone partial ligation of the 
sciatic nerve, which approached the levels prior to nerve ligation. This indicates that the 
conotoxins have an anti-allodynic effect in this neuropathic pain model. The potency and efficacy 
of CVID and MVIIA were similar to that observed in prior studies which have examined the 
effects of the conotoxins in neuropathic and inflammatory pain models (Malmberg & Yaksh, 
1995; Scott et al., 2002; Smith et al., 2002). It was also observed that MVIIA, but not CVID and 
the hybrid conotoxins, transiently increased thermal PWL to values above the pre-PNL level, 
indicating that MVIIA produced thermal hypoalgesia. The weak effect of these conotoxins on 
thermal pain is consistent with the lack of effect of MVIIA and CVID on hot-plate latency in a 
neuropathic pain model (Scott et al., 2002). It might be noted, however, that MVIIA reduces 
thermal hyperalgesia in the chronic constriction injury model, but not in the spinal nerve ligation 
model (Yamamoto & Sakashita, 1998). These findings indicate that conotoxins may be 
particularly effective in targeting mechanical allodynia in neuropathic pain models.  
 
The reduction in allodynia produced by the conotoxins was associated with side-effects which 
included reduced motor performance on the rotarod, plus visually scored behaviours ranging 
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from piloerection and twitching to seizures at the highest doses tested (Scott et al., 2002; Smith 
et al., 2002). We measured the therapeutic index of CVID and MVIIA as the ratio of their ED50s 
for anti-allodynia versus side-effect induction. The therapeutic index for CVID and MVIIA was 
1.8 and 1.0, respectively, when comparing rotarod performance, and was 2.4 and 0.7, 
respectively, when comparing the visually scored behaviours. The present results differ from a 
previous study in which CVID (9.7) had a greater therapeutic index than MVIIA (2.1) in a 
neuropathic model (Scott et al., 2002). The difference between these studies might be due to the 
use of different neuropathic pain models (partial sciatic nerve ligation versus tight spinal nerve 
ligation). It might be noted that a relatively high therapeutic index has also been observed for 
intrathecal CVID in an animal model of inflammation (Smith et al., 2002). The difference might 
also be due to the additional assessment of motor incoordination with the rotarod test in the 
present study. Indeed, CVID had only a 1.7x greater therapeutic index than MVIIA when using 
the rotarod test as a side-effect measure. By comparison, our study and that by Scott et al. (2002) 
found that CVID had a 3.7x and a 4.6x greater therapeutic index than MVIIA, respectively, when 
using the visual scoring system. This suggests that the rotarod provides a more sensitive side-
effect measure than the visual scoring system, at least for conotoxins, and that a range of side-
effects should be examined when assessing the therapeutic index of analgesics.  
 
In order to determine the mechanism underlying the differences between the functional analgesic 
properties of these conotoxins we examined their effect on primary afferent evoked synaptic 
transmission in a spinal pain pathway. Potential differences between the conotoxins include their 
selectivity, potency, efficacy, or site of action. In the present study, it was found that CVID and 
MVIIA both reduced non-NMDA mediated synaptic transmission into lamina II of the superficial 
dorsal horn, similar to that observed previously for the Cav2.2 selective conotoxins CVID, GVIA 
and MVIIA (Heinke et al., 2004; Rycroft et al., 2007; Motin & Adams, 2008). The inhibition of 
synaptic transmission was likely to be mediated by presynaptic inhibition of neurotransmitter 
 16 
release from primary afferent nociceptor terminals within the dorsal horn. Firstly, EPSC were 
evoked by focal stimulation of the dorsal roots which contain primary afferent fibres, as in other 
studies (Heinke et al., 2004; Rycroft et al., 2007; Motin & Adams, 2008). Secondly the CVID 
and MVIIA induced inhibition of evoked EPSCs was associated with an increase in the paired 
pulse ratio of closely evoked EPSCs, which is indicative of a presynaptic site of action and 
consistent with prior observations on Sr2+-evoked asynchronous EPSCs (Rycroft et al., 2007). In 
the current study, CVID had an EC50 of 69 nM which is similar to its potency at Cav2.2 VGCCs 
in isolated dorsal root ganglion neurons and cell-lines (Motin et al., 2007; Murali et al., 2012). 
While the maximal inhibition of evoked EPSCs was similar to that observed in some studies 
using Cav2.2 selective ω-conotoxins (Heinke et al., 2004; Rycroft et al., 2007), it was less than 
the complete inhibition observed previously (Motin & Adams, 2008). This difference might have 
been due to differences in the temperature of recordings. It may have also been due to differences 
in age because the present in vitro experiments were carried out in 2 – 3 week old rats (compared 
to less than 2 weeks old in Motin & Adams, 2008) and there are developmental changes in spinal 
VGCC expression during the first two post-natal weeks (Iwasaki et al., 2000). 
 
It has been suggested that differences in ligand unbinding from VGCCs impacts upon the 
analgesic utility of different conotoxins (Wright et al., 2000; Adams et al., 2012). The inhibition 
of VGCC currents in isolated neurons produced by CVID is much more reversible after washout 
than MVIIA, and that this is due largely to the basic amino acid residue at position 10 of the 
peptide sequence (Mould et al., 2004). This residue is an arginine in MVIIA and a lysine in 
CVID. Indeed, mutation of residue 10 to arginine in CVID to [K10R]CVID impairs the 
reversibility of VGCC inhibition, while mutation to lysine in MVIIA to [R10K]MVIIA increases 
it (Mould et al., 2004).  
 
We observed that the time course of anti-allodynia was not solely dependent upon the type of 
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amino acid at residue 10. While the conotoxins produced similar maximal anti-allodynic 
effects, CVID and [K10R]CVID had a quicker reversal of anti-allodynia following washout than 
MVIIA and [R10K]MVIIA. The time course of motor disruption produced by the conotoxins also 
mirrored the time course of anti-allodynia produced by these agents, with MVIIA having a longer 
duration of action. [K10R]CVID and [R10K]MVIIA, had a lesser effect on rotarod performance 
compared to CVID and MVIIA, although they produced similar side-effects to CVID and MVIIA 
when using the visual scoring system. It is therefore possible that the hybrid conotoxins could 
provide a potential therapeutic alternative to CVID and MVIIA, that is independent of the type of 
amino acid at residue 10.  
 
We also observed a lack of correlation between the position 10 residue and recovery from 
inhibition at the cellular level. In spinal cord slices, the inhibition of evoked EPSCs produced by 
[K10R]CVID and [R10K]MVIIA was variable, as was the recovery of evoked EPSCs following 
washout of CVID, MVIIA, [K10R]CVID and [R10K]MVIIA. This variability in recovery was 
dependent upon the degree of inhibition, but was independent of the conotoxin type. This differs 
to the findings for VGCC inhibition in isolated neurons where recovery is dependent upon both 
the degree of inhibition and the conotoxin type (Mould et al., 2004).  
 
Together, the present experiments indicate that the in vitro actions of conotoxins in the spinal 
cord slice preparation and their in vivo effects following intrathecal delivery are largely 
determined by factors other than the residue at position 10. Ligand induced inhibition and 
unbinding from VGCCs is influenced by the state of depolarisation (Lewis et al., 2012), and 
unlike the experimental conditions used to study VGCCs in isolated neurons, presynaptic 
terminals in spinal cord slices and in whole animals are not held under voltage clamp conditions. 
The actions of conotoxins are also influenced by VGCCs auxiliary subunits (Mould et al., 2004; 
Lewis et al., 2012) and these are altered in neuropathic pain models (Li et al., 2004; Boroujerdi et 
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al., 2008). In this regard, the cellular actions of conotoxins in the present and prior slice studies 
have been carried out using tissue from naïve animals. While there are no conotoxins studies 
using slices from neuropathic animals, it might be noted than CVID inhibition of evoked EPSCs 
is reduced in an inflammatory pain model (Rycroft et al., 2007). Finally, the actions of 
conotoxins are likely to be limited by their distribution and metabolism. In this regard, the 
conotoxins are likely to have relatively poor access to binding sites within presynaptic terminals 
in whole animals and the slice preparation compared to isolated neurons, which could provide a 
rate limiting step in their reversibility.  
 
In summary, the present study indicates that the conotoxins CVID and MVIIA both reduce the 
mechanical allodynia associated with an animal model of neuropathic pain. Unlike prior studies, 
the current results suggest that CVID has only a marginally better greater therapeutic index that 
MVIIA. Two intermediate hybrids, [K10R]CVID and [R10K]MVIIA, displayed lesser disruption 
of motor performance, however, they still displayed other side-effects. CVID, MVIIA and the 
hybrids inhibited primary afferent evoked synaptic transmission into the superficial dorsal horn in 
a similar manner. Alteration of residues in these conotoxins might therefore present an alternative 
approach to improving the therapeutic index of these analgesic agents.  
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Table 1. Potency and therapeutic index CVID and MVIIA 
_________________________________________________________________________ 
   CVID    MVIIA 
   ED50   TI ED50   TI 
_________________________________________________________________________ 
Mechanical PWT 0.04 (0.02 - 0.10)  0.06 (0.04 – 0.08) 
Rotarod  0.08 (0.05 - 0.12) 1.8 0.06 (0.04 – 0.08) 1.0 
Side-Effect Score 0.11 (0.06 - 0.19)  2.4 0.04 (0.02 – 0.06) 0.7 
_________________________________________________________________________ 
 
ED50 in nmol, shown as mean (95% confidence interval). The therapeutic index (TI) was 
calculated as the ratio of the ED50 for mechanical PWT:rotarod, and mechanical PWT:visual 
side-effect score. 
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Figure 1. Time course of action of conotoxins in a neuropathic pain model. Time plots of 
the effect of CVID, [K10R]CVID, [R10K]MVIIA, MVIIA (0.1 nmol) or vehicle on (A) 
mechanical paw withdrawal threshold (PWT), (B) thermal paw withdrawal latency (PWL), and 
(C) rotarod latency. Animals received an intrathecal injection of one of the conotoxins, or a 
matched vehicle at time 0 h, 14 days after partial nerve ligation (Post-PNL). Data is also shown 
prior to PNL surgery (Pre-PNL). *, ** and *** denotes p < 0.05, 0.01, and 0.001 compared to 
vehicle at the corresponding time point. Data for rotarod latency is shown as the difference to that 
at time 0, prior the drug injection.  
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Figure 2. Conotoxins have dose dependent effects in a neuropathic pain model. Bar charts 
of the net effect of intrathecal injection of CVID, [K10R]CVID, [R10K]MVIIA, MVIIA and 
matched vehicle on (A) mechanical paw withdrawal threshold (PWT), (B) rotarod latency and 
(C) side-effect score. Plots of the net effect on (D) rotarod latency and (E) side-effects score 
versus mechanical PWT, for dose in which there significant effect on mechanical PWT. The net 
effect was measured as the average over 1 – 2 hours post-drug injection as a percentage of the 
maximum possible effect (% MPE). *, ** and *** P < 0.05, 0.01 and 0.0001 compared to 
vehicle. The dotted lines in (D - E) indicate where there was an equal effect on both behavioural 
assays. 
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Figure 3. CVID produces concentration dependent presynaptic inhibition of evoked 
EPSCs in superficial dorsal horn. (A) Time plot of the amplitude of dorsal root evoked EPSCs 
in a lamina II neuron during superfusion of CVID 30 nM, then 300 nM. (B) Averaged traces of 
evoked EPSCs before (Pre) and during application 30 and 300 nM CVID. (C) Averaged evoked 
EPSCs in response to identical paired stimuli (inter-stimulus interval 70 ms) before (Pre) and 
during 30 and 300 nM CVID, with EPSC1 normalized to demonstrate relative facilitation of 
EPSC2 during superfusion of CVID. (D) Concentration response curve for the inhibition of 
evoked EPSC amplitude by CVID, with a logistic function fitted to determine the EC50. In (D) 
data is shown as the evoked EPSC amplitude in the presence of CVID as a percentage of the pre-
CVID value. 
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Figure 4. Conotoxins inhibit evoked EPSCs in superficial dorsal horn. Averaged traces of 
evoked EPSCs before (Pre) and during application of 100 nM (A) [K10R]CVID, (B) 
[R10K]MVIIA and (C) MVIIA. (D) Scatter plots of the reduction in evoked EPSCs produced by 
the conotoxins, shown as the evoked EPSC amplitude in the presence of conotoxin as a 
percentage of the pre-conotoxin value. In (D) lines show mean ± s.e.mean; *, ** and *** p < 
0.05, 0.01, 0.001 (drug versus pre-drug) and # p < 0.05 ([R10K]MVIIA versus CVID, 
[K10R]CVID and MVIIA). 
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Figure 5. Recovery from conotoxin inhibition is dependent upon the degree of inhibition. 
(A – B) Time plots of the amplitude of dorsal root evoked EPSCs in two different lamina II 
neurons during superfusion of 100 nM MVIIA (shaded area), with recovery during 20 min of 
washout. (C) Scatter plots of the recovery of evoked EPSC amplitude following washout of 
CVID, [K10R]CVID, [R10K]MVIIA and MVIIA; data shown as the evoked EPSC amplitude at 
20 min post-wash as a percentage of the pre-conotoxin application value. (D) Plot of the recovery 
of evoked EPSC amplitude following 20 min wash (eEPSC wash) versus the inhibition of evoked 
EPSC amplitude during conotoxin application (eEPSC Drug); both values expressed as a 
percentage of the pre-conotoxin application value. In (C) lines show mean ± s.e.mean; *, ** and 
*** p < 0.05, 0.01, 0.001 (wash versus pre-drug). In (D) the linear best-fit line to all conotoxins is 
shown. 
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